Richard Allen, DO
Family Medicine · Lansing, MINPI 1679694582
Payments from drug & device makers
Across 265 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$736
- Lilly USA, LLC$563
- AstraZeneca$555
- AbbVie$472
- Pfizer$379
- GSK$222
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,333100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $736 |
| Lilly USA, LLC | 39 | $563 |
| AstraZeneca | 24 | $555 |
| AbbVie(2 entities) | 35 | $472 |
| Pfizer | 22 | $379 |
| GSK | 12 | $222 |
| Boehringer Ingelheim | 10 | $159 |
| Abbott | 8 | $152 |
| Bayer | 9 | $149 |
| Exact Sciences | 7 | $127 |
| Eisai Inc. | 5 | $102 |
| Merck | 6 | $101 |
| Dexcom, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 4 | $66 |
| Phadia US Inc. | 4 | $57 |
| Amgen | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Organon | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $27 |
| Biomarin Pharmaceutical Inc. | 1 | $24 |
| Neurelis, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Fortovia Therapeutics, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,333 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 65 | $101,851 |
| EliquisApixaban | 61 | $76,928 |
| JardianceEmpagliflozin | 41 | $69,872 |
| TrulicityDulaglutide | 48 | $50,414 |
| JanuviaSitagliptin Phosphate | 38 | $41,780 |
| FarxigaDapagliflozin Propanediol | 25 | $40,685 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $36,840 |
| OzempicSemaglutide | 23 | $25,723 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $25,544 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $21,981 |
| XareltoRivaroxaban | 12 | $17,986 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,574 |
| Atorvastatin Calcium | 445 | $7,918 |
| Losartan Potassium | 361 | $5,594 |
| Tamsulosin Hcl | 182 | $4,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $563 | $152,265113 claims |
| PfizerEliquis, Paxlovid | $379 | $81,02373 claims |
| Boehringer IngelheimJardiance | $159 | $69,87241 claims |
| MerckJanuvia, Janumet | $101 | $67,32454 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $555 | $62,66647 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $222 | $45,41452 claims |
| Novo NordiskOzempic | $736 | $25,72323 claims |
| Johnson & JohnsonXarelto | $13 | $17,98612 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $13 | $3,65613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Lansing
- Farhan BhattiLansing$230K
- David WeismantelLansing$180K
- Laurie RozekLansing$86K
- Amy TrinhLansing$19K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.